Type 2 diabetes
European Commission has granted marketing authorization in Europe. For Sanofi’s Suliqua, a once-daily injection for the treatment of adults with Type 2 diabetes. Suliqua is authorize for use in combination with metformin to improve glycemic control. When this has not been provided by metformin alone. Or metformin combine with another oral glucose. Lowering medicinal product or with basal insulin. Suliqua will be deliver in two pre-fill SoloSTAR pens, providing different dosing options that may help answer individual market and patient insulin needs. The differentiation between the pen strengths is based on the dose range and ratios of each pen.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.